Brexpiprazole: A molecule that should be on your radar

Brexpiprazole CAS# 913611-97-9Brexpiprazole is a drug used to either treat Schizophrenia or to prevent its relapse. It is also approved for use as an adjuvant in the treatment of Major Depressive Disorder (MDD), as an add-on when first line antidepressants fail to provide sufficient clinical results. Brexpiprazole has been launched under the brand name Rexulti.

Brexpiprazole was considered a major newcomer in 2015, with the potential to become the next blockbuster in mental health disorders. Drugs used in mental health have always maintained their position in top ten selling groups of drugs globally, and will continue to do so as per the IMS Institute for Healthcare Informatics report titled “Global Outlook for Medicines Through 2018”.

Brexpiprazole is classified as an atypical antipsychotic and adjunctive antidepressant, having a dopamine and serotonin receptor partial agonism. It is very similar in action to Aripiprazole (better known as Abilify), which has long maintained its position as one of the top 10 selling drugs in the US, and as one of the best-selling drugs for mental health globally. Brexpiprazole offers the benefit of improved pharmacokinetics and safety profile (lesser extrapyramidal side effects like restlessness and agitation). This is especially important, as both Schizophrenia and MDD are chronic diseases.

If Brexpiprazole isn’t in your portfolio, then this is a molecule that should be on your radar, especially if you are a company that provides solutions for mental health. It’s truly a molecule with potential to become the next blockbuster. Most gurus of the pharma market have included this molecule in the list of drugs to look out for.

LGM Pharma is a trusted supplier of APIs that can assist you in acquiring Brexpiprazole CAS# 913611-97-9 for carrying out clinical trials, or for creating new formulations, dosages and/or delivery systems.


General disease facts

Schizophrenia is a very severe, debilitating and chronic mental condition. In this condition, a person loses touch with reality. It is characterized by hallucinations, a disorder of thought process, and movements. In most cases, there is a severe decline in cognitive function. Though this disease is not as common as many other mental disorders, it starts at quite a young age with most patients having symptoms before the age of 30. This condition cannot be cured, thus patients need lifelong treatment with drugs.

Major depressive disorder (MDD) is a serious mood disorder, often requiring multi-drug therapy to control the symptoms. In this condition, a person loses interest in daily activities, and stops enjoying life. A person with MDD often becomes hopeless, pessimistic, and irritated. A loss of appetite, weight change and a change in sleep pattern is common. In addition, many MDD sufferers show suicidal tendencies if not treated.